CBI-3A Adjuvant Platform
Vaccine enhancement for various pathogens
Pre-clinicalActive
Key Facts
Indication
Vaccine enhancement for various pathogens
Phase
Pre-clinical
Status
Active
Company
About Clarus Biologics
Clarus Biologics is a private, pre-clinical stage biotech focused on developing a novel VLP-based adjuvant platform, CBI-3A, to address key challenges in modern vaccinology. The company's technology aims to elicit broad adaptive and innate immune responses, offers antigen-sparing capabilities, and has demonstrated preclinical proof-of-concept across multiple species and antigens. Led by a team of industry veterans, Clarus is positioning its platform for partnerships and licensing to accelerate the development of more effective prophylactic and therapeutic vaccines.
View full company profile